Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

The Avalanche Approach

Currently, wet age-related macular degeneration is treated with frequent injections of anti-VEGF protein directly into the eyeball. This creates a burden for both patients and physicians, and limits access for those who are not able to comply with frequent visits and injections.

Learn More About The Avalanche Approach:

Avalanche Biotechnologies to Present at the Jefferies Global Healthcare Conference

November 13, 2014

MENLO PARK, CA – November 13, 2014 – Avalanche Biotechnologies, Inc. (Nasdaq: AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced that Linda C. Bain, Chief Financial Officer, will present at the Jefferies Global Healthcare Conference on Thursday, November 20, 2014 at 8:40 am GMT in London, England.

Read More

Read All Avalanche News